Literature DB >> 25957163

Access to critical medicines: When are compulsory licenses effective in price negotiations?

Shyama V Ramani1, Eduardo Urias2.   

Abstract

Governments of developing countries can be in a vulnerable position with respect to patent protected drugs supplied by foreign firms, if the technology cannot be licensed or independently developed by local firms. In such instances, one possible solution is to negotiate for a price-drop with the patent holder in lieu of issuing a compulsory license. The present paper develops a game theoretic model of such bargaining and shows that while compulsory licenses do not occur under complete information, they can be issued under incomplete information. The model is tested against real episodes of compulsory licenses to derive policy insight.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Keywords:  Access to medicines; Compulsory licensing; IPR; Non-cooperative game; Price negotiation; TRIPS

Mesh:

Substances:

Year:  2015        PMID: 25957163     DOI: 10.1016/j.socscimed.2015.04.023

Source DB:  PubMed          Journal:  Soc Sci Med        ISSN: 0277-9536            Impact factor:   4.634


  5 in total

1.  Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis.

Authors:  Swathi Iyengar; Kiu Tay-Teo; Sabine Vogler; Peter Beyer; Stefan Wiktor; Kees de Joncheere; Suzanne Hill
Journal:  PLoS Med       Date:  2016-05-31       Impact factor: 11.069

2.  Is pricing of dolutegravir equitable? A comparative analysis of price and country income level in 52 countries.

Authors:  Joel Sim; Andrew Hill
Journal:  J Virus Erad       Date:  2018-10-01

3.  Importance of the intellectual property system in attempting compulsory licensing of pharmaceuticals: a cross-sectional analysis.

Authors:  Kyung-Bok Son
Journal:  Global Health       Date:  2019-06-27       Impact factor: 4.185

4.  Country versus pharmaceutical company interests for hepatitis C treatment.

Authors:  Roy Lothan; Noa Gutman; Dan Yamin
Journal:  Health Care Manag Sci       Date:  2022-08-24

5.  Pathways to ensure universal and affordable access to hepatitis C treatment.

Authors:  Caitlin H Douglass; Alisa Pedrana; Jeffrey V Lazarus; Ellen F M 't Hoen; Radi Hammad; Ricardo Baptista Leite; Andrew Hill; Margaret Hellard
Journal:  BMC Med       Date:  2018-10-09       Impact factor: 8.775

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.